Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Were $723.7M As Of September 30, 2024, Which Is Anticipated To Fund Operations At Least Into The Second Half Of 2026
Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Were $723.7M As Of September 30, 2024, Which Is Anticipated To Fund Operations At Least Into The Second Half Of 2026
戴納基的現金、現金等價物和市場證券截至2024年9月30日爲72370萬美元，預計能夠支持至少到2026年下半年的運營。
Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Were $723.7M As Of September 30, 2024, Which Is Anticipated To Fund Operations At Least Into The Second Half Of 2026
戴納基的現金、現金等價物和市場證券截至2024年9月30日爲72370萬美元，預計能夠支持至少到2026年下半年的運營。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間